The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-β Peptide Export Activity of P-Glycoprotein.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Jan 2022
Historique:
received: 30 12 2021
revised: 12 01 2022
accepted: 16 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 9 3 2022
Statut: epublish

Résumé

The ATP-binding cassette transporter, P-glycoprotein (P-gp), has been demonstrated to facilitate the clearance of amyloid-beta (Aβ) peptides, exporting the neurotoxic entity out of neurons and out of the brain via the blood-brain barrier. However, its expression and function diminish with age and in Alzheimer's disease. P-gp is known to undergo ubiquitination, a post-translational modification that results in internalisation and/or degradation of the protein. NEDD4-1 is a ubiquitin E3 ligase that has previously been shown to ubiquitinate P-gp and reduce its cell surface expression. However, whether this effect translates into altered P-gp activity remains to be determined. siRNA was used to knockdown the expression of Nedd4 in CHO-APP cells. Western blot analysis confirmed that absence of Nedd4 was associated with increased P-gp protein expression. This was accompanied by increased transport activity, as shown by export of the P-gp substrate calcein-AM, as well as enhanced secretion of Aβ peptides, as shown by ELISA. These results implicate Nedd4 in the regulation of P-gp, and highlight a potential approach for restoring or augmenting P-gp expression and function to facilitate Aβ clearance from the brain.

Identifiants

pubmed: 35162941
pii: ijms23031019
doi: 10.3390/ijms23031019
pmc: PMC8834788
pii:
doi:

Substances chimiques

ABCB1 protein, human 0
APP protein, human 0
ATP Binding Cassette Transporter, Subfamily B 0
Amyloid beta-Protein Precursor 0
Fluoresceins 0
calcein AM 148504-34-1
Nedd4 Ubiquitin Protein Ligases EC 2.3.2.26
Nedd4 protein, human EC 2.3.2.26

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Ann Neurol. 2014 Dec;76(6):837-44
pubmed: 25205593
Sci Rep. 2016 Oct 27;6:36134
pubmed: 27786305
Neuropharmacology. 2014 Apr;79:668-78
pubmed: 24467845
Cell Death Dis. 2019 Dec 2;10(12):904
pubmed: 31787758
Cell. 2010 Nov 24;143(5):682-5
pubmed: 21111229
Neurobiol Aging. 2009 Nov;30(11):1818-24
pubmed: 18358568
Front Genet. 2018 Feb 14;9:29
pubmed: 29491882
J Biol Chem. 2015 Oct 2;290(40):24604-13
pubmed: 26296893
Cancer Sci. 2013 Jun;104(6):694-702
pubmed: 23465077
J Am Soc Nephrol. 2006 Jul;17(7):1807-19
pubmed: 16738015
Neurobiol Aging. 2015 Sep;36(9):2475-82
pubmed: 26159621
Gene. 2015 Feb 25;557(2):113-22
pubmed: 25527121
Science. 2010 Dec 24;330(6012):1774
pubmed: 21148344
FEBS Lett. 2017 Sep;591(17):2636-2647
pubmed: 28771691
J Neural Transm (Vienna). 2018 Feb;125(2):177-191
pubmed: 29196815
J Nucl Med. 2014 Jul;55(7):1106-11
pubmed: 24842892
Brain Res. 2010 Oct 28;1358:228-38
pubmed: 20727860
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Neurosci Lett. 2011 Jan 10;487(3):389-93
pubmed: 21047545
J Neurochem. 2001 Feb;76(4):1121-8
pubmed: 11181832
Transl Neurodegener. 2020 May 7;9(1):16
pubmed: 32381118
Brain. 2012 Jan;135(Pt 1):181-9
pubmed: 22120145
J Pathol. 2009 Jun;218(2):248-55
pubmed: 19274672
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383667
FEBS J. 2020 Feb;287(4):612-625
pubmed: 31750987
PLoS One. 2021 Apr 26;16(4):e0250371
pubmed: 33901197
Mol Pharmacol. 2010 May;77(5):715-23
pubmed: 20101004
Nat Rev Neurol. 2015 Aug;11(8):457-70
pubmed: 26195256
Curr Alzheimer Res. 2016;13(6):615-20
pubmed: 26971931
Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2361-70
pubmed: 26057472
Mol Membr Biol. 2015;32(2):39-45
pubmed: 26006083
FEBS Lett. 2020 Dec;594(23):4076-4084
pubmed: 33022784
Front Aging Neurosci. 2018 Jun 26;10:186
pubmed: 29997495
J Neurosci. 2016 Feb 10;36(6):1930-41
pubmed: 26865616
Mol Pharmacol. 2004 Sep;66(3):395-403
pubmed: 15322230
Pharmacogenetics. 2002 Oct;12(7):535-41
pubmed: 12360104
Am J Physiol. 1997 Aug;273(2 Pt 1):C687-702
pubmed: 9277367
Biomol Ther (Seoul). 2012 May;20(3):245-55
pubmed: 24130920

Auteurs

Amanda B Chai (AB)

School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Richard Callaghan (R)

School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK.

Ingrid C Gelissen (IC)

School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH